+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Succeeding in the Global Cancer Diagnostics Market, 2019-2023: US, Europe, Japan-Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence

  • ID: 4135703
  • Report
  • June 2019
  • Region: Global, United States, Europe
  • 1200 pages
  • VPG Market Research
1 of 2

FEATURED COMPANIES

  • Abbott
  • bioMerieux
  • DiaSorin
  • Fujirebio
  • Leica Biosystems
  • Roche
  • MORE
The author's new report is a seven country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Worldwide Market Overview
  • Estimated universe of laboratories performing cancer diagnostic testing by country.- Five year test volume and sales projections by country.
Business Opportunities and Strategic Recommendations
  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
Cancer Diagnostic Tests Over 200 current and emerging assays including:
ACTH, AFP, Beta- 2 Microglobulin, CA 15 3/27.29, CA 19- 9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon- Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron- Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S- 100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Geographic Coverage
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • UK
  • US
Market Segmentation Analysis
  • Sales and market shares of major suppliers, by individual cancer diagnostic test and country.
  • Five year test volume and sales forecasts for major cancer diagnostic tests by country and market segment, including:
  • Hospitals- Commercial/Private Laboratories- Physician Offices/Group Practices- Cancer Clinics- Ambulatory Care Centers
  • Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
  • Cancer statistics, etiology and recent developments in the U.S., Japan and five major European countries.
Current and Emerging Products
  • Review of over 200 current and emerging cancer diagnostic tests, including:
  • Biochemical Markers- Oncogenes- Growth Factors- Hormones- Colony Stimulating Factors- Lymphokines- Immunohistochemical Stains, and others.
  • Instrumentation review analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.
Technology Assessment
  • Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
  • Review of Succeeding/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
  • Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies
  • Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
Note: Product cover images may vary from those shown
2 of 2
  • Abbott
  • Affymetrix
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Fujirebio
  • Grifols
  • GSK Biologicals
  • Hologic
  • Leica Biosystems
  • Lonza
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • SeraCare
  • Siemens Healthineers
  • Takara Bio
  • Thermo Fisher
  • Wako
Note: Product cover images may vary from those shown
Adroll
adroll